So, the natural question for Spero Therapeutics (NASDAQ:SPRO) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual ...
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...
The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback